Allogene Therapeutics, Inc.

Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic CAR T cell therapies for cancer treatment. This research and development process inherently involves animal testing. The company’s SEC filings explicitly list “animal care” as a core operational service required for its business. As a pre-commercial biotech firm, its entire pipeline and valuation are predicated on preclinical research that utilizes animal models to assess the safety and efficacy of its therapeutic candidates before human trials can begin. This places animal testing at the center of its commercial activity.

The company is listed by Cruelty Free Investors among “Companies That Exploit Animals,” a designation for firms whose operations involve animal testing. For a company like Allogene, which has no approved products generating revenue, this laboratory animal use is not a peripheral activity but a fundamental, ongoing component of its drug development process. The evidence, while not detailing specific testing protocols, confirms that animal utilization is a stated and necessary part of its operations.